FDA Considers Posting Names of Unapproved Drugs

Published Online: Monday, September 1, 2003
    Concern over medication mix-ups due to ?sound-alike? drugs is causing the FDA to reconsider its longstanding opposition to public disclosure of the names of drugs still in the research and development pipeline. According to officials at the FDA?s medication error prevention branch, the agency may soon propose new procedures for placing the names of unapproved drugs on the Internet?a move that some say could reduce confusion with other products and therefore lower the potential risk of medication mix-ups for patients.

Latest Articles
Mylan has announced the US launch of clozapine orally disintegrating tablets, 25 mg and 100 mg, the generic version of Jazz Pharmaceutical’s FazaClo.
Carlos Aquino, founder and president of PharmaDiversion LLC, talks about some safeguards pharmacists can implement.
A pharmacy robber not only left his fingerprints behind at a pharmacy—he also dropped his wallet containing his identification as he made his escape.
Janssen Research and Development LLC has submitted a new drug application to the FDA for canagliflozin and metformin hydrochloride extended release (Invokamet XR).
Latest Issues